Awake fiberoptic intubation: topicalization and sedation
Why examiners ask this
An awake intubation is the answer the examiner is steering toward whenever the stem describes a predicted difficult airway, and the follow-up tests whether I can actually do it rather than just name it. It stresses application of knowledge, because the technique lives or dies on topicalization and on sedating a patient without losing the airway I am trying to protect, and judgment, because the examiner wants to hear when awake is mandatory and when it is overkill. The patient who refuses, the patient who stops breathing, and the patient who aspirates give the examiner three ready curveballs.
The 60-second answer
I choose an awake technique when I predict difficult intubation, especially with difficult face-mask or supraglottic ventilation, a high aspiration risk or intolerance of apnea, or when the airway is compromised by a mass, abscess, trauma or fixed cervical spine.1 I explain to the patient what they will feel and why, give glycopyrrolate 0.1–0.2 mg IV, which acts within 3–5 minutes, to dry secretions so the local anesthetic reaches mucosa,2 and preoxygenate with high-flow nasal oxygen. I topicalize with lidocaine, 4% nebulized or atomized to the oropharynx and 2–4% sprayed through the scope as I go, keeping the total at or below 9 mg/kg of lean body weight.2 I sedate lightly with dexmedetomidine, 1 mcg/kg over 10 minutes then 0.7 mcg/kg/h,3 or a remifentanil infusion, keeping the patient responsive to voice. I pass the scope orally or nasally, confirm carina, railroad a reinforced tube, confirm with capnography and only then induce.2
Decision points and the "why"
- Awake versus asleep — predicted difficult intubation with easy mask ventilation lets me induce with a video laryngoscope and a plan B; predicted difficulty with both, or an airway at risk of total obstruction, demands that the patient keeps breathing. I change my mind for a patient who cannot cooperate or an airway that is bleeding too much to see.
- Topicalization over nerve blocks — superior laryngeal and transtracheal blocks work but add needles, bleeding and hematoma near a difficult airway; a well-dried, well-topicalized patient tolerates the scope without them. I use the transtracheal injection when time is short and the neck is accessible.
- Dexmedetomidine as the sedative — it preserves respiratory drive and airway tone and produces a cooperative, rousable patient; the cost is bradycardia and hypotension, so I load slowly. Remifentanil blunts cough and gag but can produce apnea; either drug alone is the safest single-agent choice, while propofol as sole sedative causes more over-sedation and obstruction.2 Midazolam alone produces disinhibition and no analgesia.
- Nasal versus oral route — nasal gives a straighter path and a patient who cannot bite the scope, at the cost of epistaxis, so I use lidocaine with phenylephrine rather than cocaine2 and avoid it in coagulopathy or base-of-skull fracture. Oral with an intubating airway suits a patient going to oral surgery or ENT.
- Tube choice — a reinforced or Parker-tip tube, half a size smaller than I would normally use, passes the arytenoids with fewer hang-ups; if it catches, I withdraw slightly and rotate 90° counter-clockwise.
- Confirmation before induction — a two-point check, carina seen through the tube and capnography, then bilateral breath sounds; only then propofol.2 Inducing on a tube in the esophagus of a patient who could not be mask ventilated is the worst outcome this topic can produce.
- Antisialagogue timing — glycopyrrolate takes 3–5 minutes IV or about 20 minutes IM; it is optional, but without it the lidocaine can wash off and the scope sees only secretions.2
The complication they will inject
The patient becomes unresponsive and apneic mid-procedure, with the saturation drifting down. I recognize over-sedation combined with local anesthetic in the airway, stop the sedative and the scope, call for help, and support the airway: jaw thrust, high-flow nasal oxygen already running, and a two-handed mask if that fails. If I can ventilate, I give naloxone if an opioid was involved and let the patient wake, then decide whether to resume with less sedation or convert to a different plan. If I cannot ventilate, this is a cannot-intubate, cannot-oxygenate situation and I go to a supraglottic airway and then front-of-neck access. The other inject is local anesthetic toxicity from a generous topical dose in a small patient: perioral numbness, agitation, then seizure, and I treat with benzodiazepine and 20% lipid emulsion 1.5 mL/kg over 2–3 minutes.4
Pitfalls that cost points
- Naming "awake fiberoptic" without describing drying, topicalization and sedation target.
- Sedating to the point of unresponsiveness and calling it awake.
- Forgetting that topical lidocaine counts toward the toxic total.
- Inducing before capnographic confirmation.
- Offering awake intubation for every difficult-looking airway without weighing the cooperative patient against the uncooperative one.
Rapid-why
Q: Why does the patient still cough when I reach the cords after a good oropharyngeal spray? A: Sensation below the cords is from the recurrent laryngeal nerve; I spray 2 mL of lidocaine through the scope onto the cords and into the trachea, or do a transtracheal injection.
Q: Why is an unanticipated aspiration risk higher during awake intubation? A: Topicalization abolishes the laryngeal reflexes that protect the trachea; a full-stomach patient needs the shortest possible time between topicalization and a cuffed tube.
Q: Why not ketamine as the sole sedative? A: It preserves drive, but it increases secretions and produces a patient who moves and may not cooperate; combined with dexmedetomidine in small doses it works well.
Q: What if the patient refuses? A: I explore the reason, explain that the alternative carries a risk of being unable to breathe for them, and if they still refuse I plan an inhalational or careful intravenous induction with a surgeon scrubbed for a surgical airway, documenting the discussion.
Numbers to know
| Item | Value |
|---|---|
| Glycopyrrolate | 0.1–0.2 mg IV (onset 3–5 min) or 0.2–0.4 mg IM 30–60 min before2 |
| Topical lidocaine maximum | 9 mg/kg lean body weight total2 |
| Dexmedetomidine | 1 mcg/kg over 10 min, then 0.7 mcg/kg/h3 |
| Remifentanil | 0.05–0.1 mcg/kg/min, target spontaneous breathing |
| Tube size | 0.5–1.0 mm ID smaller than standard, reinforced |
| Lipid emulsion 20% for toxicity | 1.5 mL/kg, then 0.25 mL/kg/min (100 mL bolus if over 70 kg)4 |
Links
- Anticipated difficult airway and the ASA algorithm, Cannot intubate, cannot oxygenate, Airway management with cervical spine injury (coming), Anterior mediastinal mass (coming), Extubation of the difficult airway (coming)
- Atlas: Capnography: waveforms and sudden loss of ETCO2
- ASA Practice Guidelines for Management of the Difficult Airway (2022); Difficult Airway Society guidelines for awake tracheal intubation in adults
Sources
- 1.2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway · ASA, 2022 · asa2.silverchair.com
- 2.Difficult Airway Society guidelines for awake tracheal intubation (ATI) in adults · DAS, 2020 · ebi.ac.ukFull text via Europe PMC (PMC7078877); Table 3 drug doses.
- 3.PRECEDEX (dexmedetomidine) injection prescribing information · FDA / DailyMed · dailymed.nlm.nih.govAwake fiberoptic intubation: 1 mcg/kg over 10 min, then 0.7 mcg/kg/h until the tube is secured.
- 4.Checklist for Treatment of Local Anesthetic Systemic Toxicity (LAST) · ASRA Pain Medicine, 2020 · asra.com
Facts on this page were checked against these sources on Oct 14, 2026. Guidelines change; confirm doses against current institutional protocols.